Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions
February 14, 2024 | MENA, Market Access, Nordic, Orphan Drugs, Rare Disease Day, orphan medicines, rare disease, webinar
Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.
Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?
This Rare Disease Day, our Global Market Access team will compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions, asking: what does this mean for your overarching market access strategy?
Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets: register here.
In an earlier rare disease market access webinar, we explored the challenges facing orphan medicines entering key European markets. Here, we will explore some of the markets that can be neglected or forgotten about by Global teams. The rare markets if you like.
Our Global Market Access experts will explore contrasting regions to showcase the significant differences between international markets when it comes to:
- Overall and rare disease patient populations
- Access inequalities
- Time to diagnosis
- Access to innovation timelines
- Healthcare funding
- Health technology assessment frameworks
Robert Taaffe (Consultant – Global Market Access) will present his research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates.
Michelle James (Associate Consultant – Global Market Access) will showcase market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions. Michelle will focus on access in Denmark, Sweden, and Norway.
After this initial comparison, Clare Foy (Director – Global Market Access) will lead a discussion on the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy.
Learn more and register at: https://mtechaccess.co.uk/rare-disease-market-access-nordic-and-mena/
If you cannot attend the webinar but would like to know more, please register nonetheless, as all registrants will receive a recording of the webinar.
The webinar is free and open to all Market Access, HEOR, Strategic, and Commercial teams in Pharmaceutical companies. Some colleagues from other organisations may attend at the discretion of Mtech Access.
This content was provided by Mtech Access – Powered by Petauri™
Company Details
Latest Content from Mtech Access – Powered by Petauri™
Mtech Access have joined Petauri!
Mtech Access are now part of Petauri. This marks a significant and exciting milestone in our journey, and aligns with our commitment to partnering with industry to bring life-enhancing technologies...
De-mystifying the NHS – What you need to know about the NHS as a market for your health technology
Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a...
NHS primary care panel – the GP Contract and Operational Planning Guidance – Live Webinar
What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future...
The role of economic evaluation in US healthcare
Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US. They highlight important considerations for companies seeking...
What role does ICER play in US market access?
The Institute for Clinical and Economic Review (ICER) is becoming an increasingly important player in US market access. As more transformative, but costly, treatments come to market, payers must continue...
Mtech Access are exhibiting at ISPOR in the US
After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125...
Market access and reimbursement in Canada – changes at CADTH
What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health...
Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics
Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...
Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions
Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.
The pitfalls of cutting costs on systematic literature reviews: 11 common issues to avoid
Embarking on a systematic literature review is a critical step in evidence synthesis, providing a foundation for robust decision-making in the healthcare landscape. As with most things, there are ways...
- 1
- 2